Multiple myeloma, a cancer of plasma cells in the bone marrow, remains one of the most treatment-resistant malignancies in hematology, but a new real-world study offers encouraging evidence about the power of high-dose chemotherapy followed by an autologous stem cell transplant. Researchers at the First Affiliated Hospital of Xinjiang Medical University in Urumqi, China, followed fifty consecutive patients with newly diagnosed multiple myeloma who underwent high-dose intravenous melphalan with autologous peripheral blood hematopoietic stem cell transplantation, a regimen abbreviated as HDM-ASCT. Their findings, published in BMC Cancer, show that the procedure substantially deepened treatment responses, pushed a majority of patients into complete remission, and revealed a striking pattern: patients whose minimal residual disease remained undetectable for a full year after transplantation experienced no relapses at all during the study window.
The retrospective single-center analysis set out to answer two questions that matter enormously to patients and clinicians alike. First, how well does HDM-ASCT perform outside the carefully controlled environment of a clinical trial, in the messy reality of routine hospital care? Second, what does the status of minimal residual disease, or MRD, the tiny population of cancer cells that survives treatment but evades conventional detection, tell us about who will stay in remission and who will relapse? The primary endpoint of the study was progression-free survival, the length of time patients live without their disease worsening, while secondary endpoints included the depth of treatment response and MRD status measured before and after transplantation.
The technical results were unambiguous on the first question. Before receiving high-dose melphalan and their own reinfused stem cells, only 54 percent of the fifty patients had achieved a very good partial response or better, and just 30 percent had reached a complete response, meaning no detectable myeloma protein or abnormal plasma cells by standard criteria. After the transplant regimen, those figures rose dramatically: 82 percent of patients achieved at least a very good partial response, and the complete response rate doubled to 62 percent. The MRD negativity rate, measured by sensitive methods capable of spotting one cancer cell among many thousands of normal ones, climbed from 44.4 percent before transplantation to 64.4 percent afterward. In other words, the procedure converted a substantial fraction of patients from partial responders into deep responders, a shift widely associated with better long-term outcomes in myeloma.
Equally important was the safety profile. All fifty patients achieved hematopoietic reconstitution, meaning their blood-forming system recovered after the intense chemotherapy wiped out their bone marrow, and there were no deaths related to the transplant itself. Transplant-related mortality has historically been one of the chief risks of autologous transplantation, so a zero percent rate in a real-world cohort is a meaningful signal that the procedure can be delivered safely in experienced centers. As of October 31, 2023, the median follow-up time was 25 months, ranging from 7.5 to 49.5 months. During that period, twelve patients experienced relapse and five died. The estimated three-year progression-free survival rate was 70.5 percent, and the estimated three-year overall survival rate was 88.4 percent, figures that compare favorably with published outcomes from larger trial populations.
The study also confirmed a principle that oncologists have long observed: depth of response matters. Patients who achieved a complete response or a very good partial response after HDM-ASCT had significantly longer estimated three-year progression-free survival than patients who reached only a partial response, with p-values of 0.039 and 0.047 respectively. This statistical association reinforces the idea that the goal of myeloma therapy should be to push the disease as close to eradication as possible, because every increment of deeper response appears to translate into more time before the cancer returns. It also suggests that pre-transplant induction therapy, which prepares patients for the transplant, plays a critical role in setting the stage for success.
The MRD findings were more nuanced but arguably more intriguing. Patients who were MRD-negative before transplantation had an estimated three-year progression-free survival of 84.7 percent, compared with 62.8 percent for those who were MRD-positive. After transplantation, the corresponding figures were 80.5 percent versus 57.6 percent. In both cases, MRD-negative patients fared numerically better, but the differences did not reach statistical significance, with p-values of 0.34 and 0.15. The authors are careful to note this limitation, and the relatively small cohort of fifty patients likely reduced the statistical power to detect what may be a real effect. Larger studies will be needed to determine whether single-timepoint MRD status reliably predicts progression-free survival in this setting.
Where the data became genuinely compelling was in the twelve-month landmark analysis. Among twenty-two patients who maintained sustained MRD negativity for at least one year after transplantation, not a single relapse occurred. By contrast, six of the fourteen patients who failed to sustain MRD negativity for that duration experienced disease progression. The difference was statistically robust, with a log-rank p-value of 0.001 and a Fisher exact test p-value of 0.0015. This finding suggests that the durability of MRD negativity, rather than its mere presence at any single moment, may be the key prognostic signal. A patient whose disease remains undetectable by sensitive assays for a full year appears to occupy a fundamentally different risk category than one whose MRD status fluctuates or turns positive again.
The authors themselves frame this observation as exploratory, and that caution is warranted. The cohort was small, the analysis was retrospective, and the follow-up, while adequate, is still measured in years rather than decades. Sustained MRD negativity could be a genuine therapeutic milestone that protects against relapse, or it could simply be a marker identifying patients with biologically indolent disease who were destined to do well regardless. Disentangling cause from correlation will require prospective studies with larger numbers of patients and longer observation periods. Still, the practical implication for clinical monitoring is clear: regular MRD testing after autologous transplantation appears valuable, and a full year of sustained negativity may eventually serve as a trigger for de-escalating therapy or, conversely, for intensifying treatment in patients who lose MRD-negative status.
One of the most reassuring aspects of the study concerns genetics. Multiple myeloma is stratified by cytogenetic abnormalities, with certain chromosomal lesions conferring high risk and poorer prognosis. In this cohort, the estimated three-year progression-free survival was 71.9 percent for patients with standard-risk cytogenetic abnormalities and 66.0 percent for those with high-risk abnormalities, a difference that was not statistically significant with a p-value of 0.402. While the numbers are numerically lower for the high-risk group as expected, the relatively narrow gap suggests that HDM-ASCT, combined with modern induction therapy, may partially blunt the adverse impact of high-risk genetics, at least over the follow-up period studied. This is a hypothesis that demands confirmation in larger cohorts, but it offers a glimmer of hope for patients whose disease carries the most dangerous chromosomal signatures.
Taken together, the study delivers a three-part message to the myeloma community. High-dose melphalan with autologous stem cell transplantation remains a safe and highly effective tool in the real world, capable of doubling complete response rates and pushing nearly two-thirds of patients into MRD-negative status. Deeper responses before and after transplantation correlate with longer progression-free survival, reinforcing the value of aggressive induction and consolidation. And sustained MRD negativity over twelve months may represent one of the most powerful predictors of durable remission yet identified in this setting, with zero relapses among patients who achieved it. As MRD-guided treatment strategies move toward the center of myeloma care, studies like this one, grounded in everyday clinical practice rather than idealized trial conditions, provide the evidence base clinicians need to make the monitoring and treatment decisions that will shape each patient’s future.
Subject of Research: High-dose melphalan autologous stem cell transplantation and minimal residual disease monitoring in multiple myeloma
Article Title: High-dose melphalan and autologous stem cell transplantation in multiple myeloma: efficacy and minimal residual disease’s impact on progression-free survival
Article References: Chen, M., Chen, G., Xu, J., Zhang, K., Yang, R., Han, C., Hou, J., Jiang, M., & Yuan, H. (2026). High-dose melphalan and autologous stem cell transplantation in multiple myeloma: efficacy and minimal residual disease’s impact on progression-free survival. BMC Cancer. https://doi.org/10.1186/s12885-026-17060-5
Image Credits: AI Generated
DOI: 10.1186/s12885-026-17060-5
Keywords: multiple myeloma, high-dose melphalan, autologous stem cell transplantation, minimal residual disease, progression-free survival, complete response, hematopoietic reconstitution, cytogenetic risk, relapse, BMC Cancer, High-dose, melphalan
News Source: Nathaniel Bowman. (October 5, 2026). Stem Cell Transplant Deepens Myeloma Response, and a Year of MRD Negativity May Signal Lasting Remission. Scienmag.
